Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Scratching the surface: the processing of pain from deep tissues

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Managing chronic pain in survivors of torture

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Persistent pain following groin hernia repair: what is the best practice in pain management?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Prescribing opioids for chronic noncancer pain: predicting response and assessing risk factors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The chronobiology of migraine: a systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Opening of BKCa channels causes migraine attacks: a new downstream target for the treatment of migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Opening of ATP sensitive potassium channels causes migraine attacks with aura

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Fremanezumab is a humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide and is approved in Europe for migraine prevention in adults with ≥4 migraine days/month. The Pan-European Real Life (PEARL) study is a 24-month, prospective, observational study of fremanezumab in chronic or episodic migraine. End points include proportion of patients with ≥50% reduction in monthly migraine days during 6 months of treatment (primary); changes in monthly migraine days, disability scores and acute headache medication use; adherence and persistence; and effectiveness in patients switching from another calcitonin gene-related peptide pathway-targeting monoclonal antibody. PEARL is being conducted in approximately 100 centers in 11 European countries (estimated n = 1100). PEARL will generate important real-world data on effectiveness of fremanezumab and treatment patterns in patients with chronic migraine or episodic migraine.

OriginalsprogEngelsk
TidsskriftPain Management
Vol/bind11
Udgave nummer6
Sider (fra-til)647-654
Antal sider8
ISSN1758-1869
DOI
StatusUdgivet - nov. 2021

ID: 66500888